NRC Form 374
(5-84)

U.S. NUCLEAR REGULATORY COMMISSION

CORRECTED COPY

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93 – 438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. Sunnyside Medical Center	3. License number 12-20431-01
2. 4527 North Pulaski Road Chicago, IL 60630	4. Expiration date October 31, 1988
	5. Docket or Reference No. 030-18690

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Iodine-125	A. Sealed sources (Amersham Model IMC.P2 or AECL Model C-324)	A. 2 sources not to exceed 500 millicuries

9. Authorized Use

A. For use in Lixiscope Model LSM-82-209 for diagnostic imaging of human extremities.

CONDITIONS

10. Licensed material shall be used and stored at Sunnyside Medical Center, 4527 North Pulaski Road, Chicago, Illinois or Podiatry Medical Center, 4051 West 63rd Street, Chicago, Illinois.

11. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 19, "Notices, Instructions and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."

12. Notwithstanding the provisions of Section 35.3(b) and 35.13 of 10 CFR Part 35, and pursuant to Section 30.11(a) of 10 CFR Part 30, the lixiscope may be used by, or under the supervision and in the physical presence of the following individuals on those portions of the human body upon which they are authorized by their state license to practice podiatry: Matthew G. Garoufalis, D.P.M., Malcolm D. Herzog, D.P.M., Ronald L. Kessler, D.P.M., Seymour Kessler, D.P.M., John S. Ling, D.P.M., Hartley L. Miltchin, D.P.M., Gregg Sponsky, D.P.M., Denise M. Turski, D.P.M. or Angeles M. Valdes, D.P.M.

COPY 4

13. A. (1) Each sealed source containing licensed material, other than Hydrogen 3, with a half-life greater than thirty days and in any form other than gas shall be tested for leakage and/or contamination at intervals not to exceed six months. In the absence of a certificate from a transferor indicating that a test has been made within six months prior to the transfer, a sealed source received from another person shall not be put into use until tested.

(2) Notwithstanding the periodic leak test required by this condition, any licensed sealed source is exempt from such leak tests when the source contains 100 microcuries or less of beta and/or gamma emitting material or 10 microcuries or less of alpha emitting material.

B. The test shall be capable of detecting the presence of 0.005 microcurie of radioactive material on the test sample. The test sample shall be taken from the sealed source or from the surfaces of the device in which the sealed source is permanently mounted or stored on which one might expect contamination to accumulate. Records of leak test results shall be kept in units of microcuries and maintained for inspection by the Commission.

C. If the test reveals the presence of 0.005 microcurie or more of removable contamination, the licensee shall immediately withdraw the sealed source from use and shall cause it to be decontaminated and repaired or to be disposed of in accordance with Commission regulations. A report shall be filed within five (5) days of the test with the U. S. Nuclear Regulatory Commission, Region III, 799 Roosevelt Road, Glen Ellyn, Illinois 60137, describing the equipment involved, the test results, and the corrective action taken.

D. The licensee is authorized to collect leak test samples in accordance with the procedures described in the Lixiscope Instruction Manual for analysis by S.A. Huber Consultants. Alternatively, leak test samples may be collected and/or analyzed by other persons specifically authorized by the Commission or an Agreement State to perform such services.

14. Sealed sources containing licensed material shall not be opened or removed from their respective source holders by the licensee.

15. The licensee may transport licensed material or deliver licensed material to a carrier for transport in accordance with the provisions of Title 10, Code of Federal Regulations, Part 71, "Packaging of Radioactive Material for Transport and Transportation of Radioactive Material Under Certain Conditions."

NRC Form 374A (5-84) U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 12-20431-01

Docket or Reference number: 030-18690

CORRECTED COPY

16. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated September 16, 1983 and application received October 17, 1983. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

For the U.S. Nuclear Regulatory Commission

Date May 31, 1985

Original Signed
By Bruce S. Mallett
Materials Licensing Section, Region III

COPY

CORRECTED COPY

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93 – 438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. Sunnyside Medical Center	3. License number 12-20431-01
2. 4527 North Pulaski Road Chicago, IL 60630	4. Expiration date October 31, 1988
	5. Docket or Reference No. 030-18690

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Iodine-125	A. Sealed sources (Amersham Model IMC.P2 or AECL Model C-324)	A. 2 sources not to exceed 500 millicuries

9. Authorized Use

A. For use in Lixiscope Model LSM-82-209 for diagnostic imaging of human extremities.

CONDITIONS

10. Licensed material shall be used and stored at Sunnyside Medical Center, 4527 North Pulaski Road, Chicago, Illinois or Podiatry Medical Center, 4051 West 63rd Street, Chicago, Illinois.

11. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 19, "Notices, Instructions and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."

12. Notwithstanding the provisions of Section 35.3(b) and 35.13 of 10 CFR Part 35, and pursuant to Section 30.11(a) of 10 CFR Part 30, the lixiscope may be used by, or under the supervision and in the physical presence of the following individuals on those portions of the human body upon which they are authorized by their state license to practice podiatry: Matthew G. Garoufalis, D.P.M., Malcolm D. Herzog, D.P.M., Ronald L. Kessler, D.P.M., Seymour Kessler, D.P.M., John S. Ling, D.P.M., Hartley L. Miltchin, D.P.M., Gregg Sponsky, D.P.M., Denise M. Turski, D.P.M. or Angeles M. Valdes, D.P.M.

COPY 3
ML38R2
5-31-85

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 12-20431-01

Docket or Reference number: 030-18690

CORRECTED COPY

13. A. (1) Each sealed source containing licensed material, other than Hydrogen 3, with a half-life greater than thirty days and in any form other than gas shall be tested for leakage and/or contamination at intervals not to exceed six months. In the absence of a certificate from a transferor indicating that a test has been made within six months prior to the transfer, a sealed source received from another person shall not be put into use until tested.

(2) Notwithstanding the periodic leak test required by this condition, any licensed sealed source is exempt from such leak tests when the source contains 100 microcuries or less of beta and/or gamma emitting material or 10 microcuries or less of alpha emitting material.

B. The test shall be capable of detecting the presence of 0.005 microcurie of radioactive material on the test sample. The test sample shall be taken from the sealed source or from the surfaces of the device in which the sealed source is permanently mounted or stored on which one might expect contamination to accumulate. Records of leak test results shall be kept in units of microcuries and maintained for inspection by the Commission.

C. If the test reveals the presence of 0.005 microcurie or more of removable contamination, the licensee shall immediately withdraw the sealed source from use and shall cause it to be decontaminated and repaired or to be disposed of in accordance with Commission regulations. A report shall be filed within five (5) days of the test with the U. S. Nuclear Regulatory Commission, Region III, 799 Roosevelt Road, Glen Ellyn, Illinois 60137, describing the equipment involved, the test results, and the corrective action taken.

D. The licensee is authorized to collect leak test samples in accordance with the procedures described in the Lixiscope Instruction Manual for analysis by S.A. Huber Consultants. Alternatively, leak test samples may be collected and/or analyzed by other persons specifically authorized by the Commission or an Agreement State to perform such services.

14. Sealed sources containing licensed material shall not be opened or removed from their respective source holders by the licensee.

15. The licensee may transport licensed material or deliver licensed material to a carrier for transport in accordance with the provisions of Title 10, Code of Federal Regulations, Part 71, "Packaging of Radioactive Material for Transport and Transportation of Radioactive Material Under Certain Conditions."

COPY

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 12-20431-01

Docket or Reference number: 030-18690

CORRECTED COPY

16. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated September 16, 1983 and application received October 17, 1983. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

For the U.S. Nuclear Regulatory Commission

Date May 31, 1985

Original Signed
By Bruce S. Mallett
Materials Licensing Section, Region III

COPY